Justin Walsh Analyst PerformanceDirector, Healthcare at JonesTradingJustin Walsh is a stock analyst at JonesTrading in the medical sector, covering 11 publicly traded companies. Over the past year, Justin Walsh has issued 10 stock ratings, including strong buy, buy, and hold recommendations. While full access to Justin Walsh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Justin Walsh's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings14 Last 1 YearsBuy Recommendations71.43% 10 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution14RatingsDistribution of strong buy, buy, hold, and sell ratings by Justin Walsh.RatingPercentageCount Strong Buy7.1%1 ratings Buy64.3%9 ratings Hold28.6%4 ratings Sell0.0%0 ratingsOut of 14 total stock ratings issued by Justin Walsh at JonesTrading, the majority (64.3%) have been Buy recommendations, followed by 28.6% Hold and 7.1% Strong Buy.Best & Worst CallsBest Call0000.0%CLNNApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%LNTHMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ81.8% of companies on NASDAQ9 companiesNYSE9.1% of companies on NYSE1 companyNYSEAMERICAN9.1% of companies on NYSEAMERICAN1 companyJustin Walsh, an analyst at JonesTrading, currently covers 11 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical11 companies100.0%Justin Walsh of JonesTrading specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies54.5%MEDICAL SERVICES1 company9.1%MED PRODUCTS1 company9.1%BIOTECHNOLOGY1 company9.1%MED - OUTP/HM CRE1 company9.1%MED - DRUGS1 company9.1% About Justin WalshJustin Walsh PhD covers biotechnology companies within the Healthcare sector. Before joining JonesTrading, Dr. Walsh was a Research Analyst at B. Riley Securities covering SMID cap biotechnology and healthcare companies with a primary focus on oncology. Earlier, he contributed to the coverage of a diverse set of biotechnology companies as an equity research associate at JMP Securities and Raymond James & Associates. He earned his PhD in chemistry from Hunter College and the City University of New York Graduate Center, wherein he collaborated with Memorial Sloan Kettering Cancer Center to study next-generation cancer imaging approaches. He holds a BA in chemistry and mathematics from Rollins College.Follow on LinkedIn Justin Walsh's Ratings History at JonesTrading Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsANROAlto Neuroscience4/2/2026Lower Price Target$22.47$44.00Buy$0.0000.00% ROINMTCNeuroOne Medical Technologies3/2/2026Initiated Coverage$4.02$9.00Buy$0.0000.00% ROILNTHLantheus2/27/2026Downgrade$75.43Hold$0.0000.00% ROIDFTXDefinium Therapeutics12/23/2025Initiated Coverage$13.30$61.00Buy$0.0000.00% ROIATAIAtai Beckley12/23/2025Initiated Coverage$4.30$16.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines9/18/2025Initiated Coverage$44.03$83.00Buy$0.0000.00% ROILNTHLantheus9/16/2025Lower Price Target$51.49$84.00Buy$0.0000.00% ROIYMABY-mAbs Therapeutics8/5/2025Downgrade$8.52Hold$0.0000.00% ROILNTHLantheus6/23/2025Lower Price Target$80.26$109.00Buy$0.0000.00% ROIVNRXVolitionRX6/10/2025Upgrade$11.13$60.00Strong-Buy$0.0000.00% ROICLNNClene4/23/2025Initiated Coverage$2.98$30.00Buy$0.0000.00% ROIMNPRMonopar Therapeutics4/2/2025Reiterated Rating$33.43Hold$00.0000.00% ROIBLRXBioLineRx4/2/2025Reiterated Rating$2.92Hold$0.0000.00% ROILNTHLantheus3/21/2025Lower Price Target$98.85$122.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
